Latest Breaking News On - Robertj deluccia - Page 1 : comparemela.com

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C difficile Infection

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobertj delucciaTrial oversight committeeDrug administrationData monitoring committeeAcurx pharmaceuticals incCompany scientific advisory boardAcurx pharmaceuticalsAdvice meetingModified intent to treatClinical cureExecutive chairmanNew drug applicationMarketing authorizationsIbezapolstat phaseScientific advisory board

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C difficile Infection

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavidp luciRobertj delucciaTrial oversight committeeAcurx pharmaceuticals incData monitoring committeeCompany scientific advisory boardEuropean medicines agency onDrug administrationAcurx pharmaceuticalsNew drug applicationMeeting requestMeeting packageBriefing documentEuropean medicines agencyScientific advice

Acurx Pharmaceuticals (ACXP) Announces Positive Extended Clinical Cure Data for Ibezapolstat

Acurx Pharmaceuticals (ACXP) Announces Positive Extended Clinical Cure Data for Ibezapolstat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davidp luciRobertj delucciaAcurx pharmaceuticals incAcurx pharmaceuticalsClinical cureExecutive chairmanExtended clinical cureSustained clinical cure

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin.

United statesUniversity of houstonDavidp luciKevin gareyRobertj delucciaAcurx pharmaceuticalsSociety or healthcare epidemiology of americaCompany phCompany scientific advisory boardExchange commissionData monitoring committeeUniversity of houston college pharmacyTrial oversight committeeEuropean medicines agencyDrug administrationExchange commission on form

Acurx Pharmaceuticals (ACXP) Reports Positive Comparative Microbiology and Microbiome Data for Ibezapolstat

Acurx Pharmaceuticals (ACXP) Reports Positive Comparative Microbiology and Microbiome Data for Ibezapolstat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of houstonDavidp luciKevin gareyRobertj delucciaAcurx pharmaceuticals incEuropean medicines agencyUniversity of houston college pharmacyAcurx pharmaceuticalsExtended clinical cureGulf coast consortia antimicrobial resistanceHouston collegePrincipal investigatorAcurx scientific advisory boardDouble blind studyIbezapolstat compared